Legato Capital Management LLC has officially submitted its latest 13F report, providing insights into its investment portfolio as of September 30, 2026. This filing is crucial for understanding the company's asset management strategies and market positioning in the financial services industry.

The report, filed on November 10, 2026, highlights Legato Capital Management's financial activities and outlines the various securities it holds. Such filings are essential for investors and analysts who track the movements of institutional investors and their strategies.

Background

Legato Capital Management LLC is a California-based investment management firm. The company is registered under the Central Index Key (CIK) number 0001442641. It operates in the financial services sector, focusing on managing assets for clients through various investment strategies. The firm has a history of filing quarterly 13F reports, with the latest submission being part of its ongoing commitment to transparency in its investment activities.

What the Filing Says

The recent filing indicates that Legato Capital Management has a total reported value of $1,109,078,714 across its portfolio. The report includes holdings in various companies, showcasing a diverse investment strategy. Notable entries include investments in companies like 10X Genomics Inc and 1st Source Corp, among others.

Impact

This filing may influence various stakeholders, including investors, analysts, and competitors within the financial services industry. By disclosing its investment positions, Legato Capital Management provides valuable information that can impact market perceptions and investment strategies of other firms, including competitors like AltraVue Capital, LLC and Bridge City Capital, LLC.

What's Next

The filing does not specify what happens next for Legato Capital Management. However, it is expected that the firm will continue to monitor its investments and adjust its portfolio in response to market conditions and investment opportunities.